Stocktoria
Turn Therapeutics Inc. TTRX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2025-10-08
Chart by TradingView
2/9
Piotroski F — financial health
-9.02
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 |
|---|---|---|
| Financials | ||
| Operating income | -$5.9M | -$1.8M |
| Net income | -$3.2M | -$1.8M |
| Operating cash flow | -$2.6M | -$1.4M |
| Total assets | $12.2M | $2.0M |
| Total liabilities | $7.5M | $2.2M |
| Shareholders' equity | $4.7M | -$177,432 |
| Ratios | ||
| Return on assets | -26.3% | -86.3% |
| Return on equity | -68.2% | 996.7% |
| Current ratio | 0.87 | 1.55 |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -9.02 (distress)
- Working capital / assets -0.066
- Retained earnings / assets -1.841
- EBIT / assets -0.482
- Equity / liabilities 0.627
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0002023016 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.